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Abstract: Recent literature suggests that mesenchymal stem/stromal cells (MSC) could be 
used as Trojan Horses to deliver “death-signals” to cancer cells. Herein, we describe the 
development of a novel multichannel cell migration device, and use it to investigate the 
relative migration rates of bone marrow-derived MSC and breast cancer cells (MCF-7) 
towards each other. Confluent monolayers of MSC and MCF-7 were established in 
adjacent chambers separated by an array of 14 microchannels. Initially, culture chambers 
were isolated by air bubbles (air-valves) contained within each microchannel, and then 
bubbles were displaced to initiate the assay. The MCF-7 cells migrated preferentially 
towards MSC, whilst the MSC did not migrate preferentially towards the MCF-7 cells. Our 
results corroborate previous literature that suggests MSC migration towards cancer cells  
in vivo is in response to the associated inflammation rather than directly to signals secreted 
by the cancer cells themselves.  
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1. Introduction 
The inability to specifically target cancer cells is a significant limitation of many cancer therapies, 
and this results in systemic off-target toxicities [1,2]. Mesenchymal stem/stromal cells (MSC) are 
multipotent stromal cells with the ability to self renew and differentiate into cells of diverse  
lineage [3]. Their hypoimmunogenicity, ease of isolation, and ease of ex-vivo modification have made 
them increasingly attractive candidates for cell-based therapies. Such MSC-based therapies have 
traditionally aimed to exploit the differentiation potential and/or the paracrine secretions of 
transplanted MSC populations to promote tissue repair and regeneration or to dampen inflammatory 
processes [4,5]. In studies where MSC were infused into healthy animals, MSC largely homed to, or 
became lodged in, highly vascularized tissues such as the lungs, liver and bones [6–9]. However, in 
animal models involving tissue injury, MSC appeared to home selectively to the sites of injury and/or 
the associated inflammation [10–12]. Tumor stroma has been described as “wounds that never heal”, 
and similarly it appears that MSC home to cancer lesions [13,14]. Based on the premise that MSC 
selectively home to cancer lesions, MSC theoretically could be utilized to specifically deliver  
“death-signals” to cancer cells [15–19]. 
The development of MSC-based delivery therapies will require precise characterization of MSC’s 
propensity to migrate to cancer cell populations and then specifically unload their “death-signal” 
payload. We utilized breast cancer epithelial cells (MCF-7) [20] as a model cell line to better 
characterize the migration behavior of bone marrow-derived MSC towards cancer cell populations. 
MSC populations migrate towards breast cancers in vivo [21]. In vitro MSC migrate towards medium 
conditioned by the more aggressive MCF-7/Ras mutant cells. This in vitro study utilized a Transwell™ 
(Tewksbury, MA, USA) assay to investigate the migration of MSC populations in response to  
MCF-7/Ras mutant conditioned medium. Whilst the Transwell™ is a robust cell migration platform 
embraced by the cell culture community, a source-sink microchannel migration device might be more 
informative, as a more robust gradient could be assured and cell migration could easily be monitored 
visually in real-time.  
In source-sink migration platforms, two large volume reservoirs are connected by a microchannel 
that enables diffusion between the reservoirs and establishes a gradient within the microchannel. The 
microchannel dimensions limit diffusive flux from one reservoir to the other, which delays the 
depletion of chemotactic signal molecules in the source reservoir and the accumulation of these 
molecules in the sink. This system maintains a reasonably stable gradient across the length of the 
microchannel, allowing the study of cell migration in response to the signal gradient generated 
between the two reservoirs.  
Source-sink microchannel devices have been previously described (reviewed in [22]), and 
commercial devices are also available (i.e., μ–Slide Chemotaxis, Ibidi GmbH, Planegg, Germany). 
Both the published devices and the commercial products establish a cell population within the 
microchannel itself, and then different chemo-attractants or controls are placed into the opposing 
reservoirs. This configuration generates a chemical gradient directly over the cell population. Neither 
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the Transwell™ system nor the existing microchannel platforms are appropriate to observe the 
migration of two different cell populations towards each other.  
Our system is a novel variation on the classic source-sink design that enables the observation of two 
cell populations migrating towards each other in response to the secretions emanating from the 
opposing cell populations. We used soft lithography to construct a device with two opposing reservoirs 
that are connected by an array of 14 microchannels. Each microchannel was initially occupied by an 
air bubble that functioned as a valve (air-valve) to isolate the two cell populations. Monolayers of 
MSC and cancer cell populations were established in opposing reservoirs, respectively. After overnight 
incubation, and visual confirmation that confluent monolayers had been established up to the edge of 
the air-filled microchannels, the air in the air-valves was displaced by briefly creating an air pressure 
differential across the microchannels. This action effectively established the source-sink configuration 
by creating continuous media contact between the two culture reservoirs. The medium on each side 
was then exchanged with fresh medium, and the migration of MSC and MCF-7 cells towards each 
other was monitored via microscopy.  
2. Experimental Section 
2.1. Cell Isolation and Culture 
MCF-7 cells were cultured in DMEM/F12 (Gibco, Grand Island, NY, USA) medium supplemented 
with 5% fetal bovine serum (FBS; Hyclone, Logan, UT, USA) and 1% penicillin/streptomycin  
(P/S; Gibco, Grand Island, NY, USA). MCF-7 cells were passaged at 80% confluence. 
Human MSC isolation and expansion: Approximately 10 mL of bone marrow aspirate were taken 
from the iliac crest of fully informed healthy volunteer donors in the Mater hospital (Brisbane, 
Australia). Ethical approval for this study was granted through the Mater Health Services Human 
Research Ethics Committee and the Queensland University of Technology in accordance with the 
Australian National Health and Medical Research Council’s Statement on Ethical Conduct in Research 
Involving Humans. Samples were diluted with phosphate-buffered saline (PBS) and mononuclear cells 
were enriched via density gradient centrifugation as described previously [23,24]. MSC were expanded 
in low-glucose DMEM (Gibco) containing 10% FBS and 1% P/S, and then sub-cultured in 
DMEM/F12 supplemented with 5% FBS and 1% P/S for one passage prior to use in migration assays 
to enable cell adaption to the base medium used in the MCF-7 monocultures and planned migration 
assays. MSC were used at passages 2 to 4.  
2.2. Device Fabrication 
Figure 1 depicts the design and dimensions of the microchannel migration device. Figure 1A shows 
the silica wafer (100 mm diameter) used to cast the bodies of three microchannel migration devices 
simultaneously. The features on the silicon wafer (3 groups of 14 rectangular features, each 1 mm 
long, 500 µm wide, and 100 µm in height) were formed using SU-8 photo resist (SU8-2025, 
MicroChem, Newton, MA, USA) as per the manufacturer’s instructions (and as described  
previously) [25]. A 4 mm deep layer of polydimethylsiloxane (PDMS, Sylgard, Dow Corning, 
Midland, TX, USA) was poured over the wafer surface and cured at 80 °C for 30 min. The cast 
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patterned PDMS was removed from the silicon wafer and trimmed to make two opposing reservoirs 
for cell culture as shown in Figure 1B. The PDMS shaped device was then plasma treated for 30 s 
(high frequency plasma generator Model BD-20, Electro-Technic Products, Chicago, IL, USA), and 
bonded to a 2 mm thick sheet of glass (Proscitech, Brisbane, Australia) and then placed on a hot plate 
(80 °C) overnight.  
Figure 1. Cell migration device. (A) The arrays of 14 microchannels are formed by casting 
polydimethylsiloxane (PDMS) over channel features on a silica wafer; (B) The resulting 
device has two reservoirs connected via an array of 14 microchannels; (C) Each reservoir 
can be filled with medium, whilst filling of the microchannels and mixing between the two 
reservoirs is initially prevented by the “air-valves”. 
 
Prior to use, the device was left dry at room temperature for at least two days. Over this time the 
plasma treated PDMS surface became hydrophobic once again [26]. This is a necessary step, as the 
microchannels must be hydrophobic for the device to function. The device was sterilized by immersion 
in 70% ethanol for 2 h, with care to ensure that the ethanol solution entered the microchannels. When 
necessary, a syringe with needle was used to displace air bubbles. Following sterilization, the ethanol 
solution was removed, and the device was left in an open sterile petri dish in a biosafety cabinet for 
two days to dry. Again, it is important that the PDMS surface is not wetted by the ethanol solution 
prior to use.  
2.3. Loading the Cell Migration Device 
To establish opposing monolayer cell populations, or control medium volumes, 1 mL of cell 
suspension and/or control media was pipetted into the appropriate reservoirs. For MCF-7 cells, 
suspensions of 500,000 cells mL−1 were loaded, whilst for MSC, 60,000 cells mL−1 were loaded via 
pipette. The difference in cell seeding densities reflects the relative spread area of the individual cell 
types and the cell numbers required to generate a confluent monolayer. Each reservoir was loaded in 
rapid succession to ensure that the air bubbles were trapped within the microchannels (Figure 1C). The 
hydrophobic nature of the material creates surface tension in the medium that deters immediate 
medium flow into the small cross-sectional opening of the microchannels. Once both reservoirs were 
filled with medium, the air bubbles in the microchannels were trapped, and the air-valve was 
stabilized. Thus, cell attachment and the formation of a monolayer were restricted to the respective 
Processes 2013, 1 353 
 
reservoirs, and cells and media were excluded from entering the microchannels. Once cell monolayers 
were established by overnight incubation, the air bubbles were displaced from the microchannels to 
create a source-sink configuration. Bubbles were displaced from the microchannels by gently 
increasing the air pressure disproportionately over one of the reservoirs, thus forcing flow into the 
opposing chamber (Figure 2). This action was performed using a custom PDMS lid, made freshly 
before use to enhance adhesiveness, which was fitted with a tube connected to an air-filled syringe 
over one of the reservoirs, and then gently expelling air from the syringe. The lid was a rectangular 
PDMS piece large enough to cover the whole reservoir surface. As both the lid and migration device 
were fabricated from PDMS they formed a strong, but reversible, electrostatic seal. Once a seal had 
been formed, approximately 1 mL of air was expelled from the syringe to displace the bubbles in  
the microchannels.  
Figure 2. (A) Air-valves initially isolate the two reservoirs, preventing fluid flow and cell 
migration into the microchannels; (B) Using a custom lid, connected to an air-filled 
syringe, the air pressure over one reservoir was increased slightly; (C) The increase in 
relative head pressure pushed the light blue fluid into the microchannels and displaced the 
air bubbles, resulting in a continuous fluidic connection between the two reservoirs. 
 
2.4. Assessing Cell Migration 
Immediately following displacement of the air bubbles from the microchannels, the medium in each 
reservoir was exchanged with fresh medium of the appropriate composition. Time zero phase contrast 
images were recorded (Nikon Eclipse TE2000-U microscope, Nikon Coolpix 4500 camera (not 
shown); Tokyo, Japan) Migration cultures were returned to the incubator (37 °C, 5% CO2), and phase 
contrast images were recorded again at days 1, 3 and 5. Parallel cultures were also terminated, cells 
were fixed in 4% paraformaldehyde and nuclei stained with DAPI (Sigma, St. Louis, MO, USA) 
Fluorescent images were recorded using the previously described microscope, and cell migration 
distances were quantified using Image J software (Version #1.47; NIH: Bethesda, MD, USA) Cell 
migration was characterized by measuring the distance of the cell wave-front in the microchannels 
from the edge of the channel for cancer cell lines, and by averaging the migrated distance of each 
single cell inside the channel for MSC populations (see Figure 3). Tracking the movement of 
individual MSC was required, as MSC did not migrate as a uniform multi-cellular wave-front. 
  
Processes 2013, 1 354 
 
Figure 3. Characterization and quantification of cell migration down the microchannels. 
(A) MCF-7 cells migrate as a wave front down the microchannels. The distance from the 
microchannel edge “D” is estimated as the distance from the corner of the channel to the 
average position of the wave front; (B) Mesenchymal stem/stromal cells (MSC) migration 
is estimated by tracking the distance travelled by individual cells as MSC do not generate a 
uniform wave front. Scale bar = 100 μm. 
 
2.5. Cell Migration Study Design 
In all cases the migration of MCF-7 cells and MSC towards each other was quantified, whilst also 
quantifying the migration of cells towards cell-free medium of similar serum supplementation  
(5% FBS = negative control), and cell-free medium supplemented with double the serum content  
(10% FBS = positive control). Although it is possible to conduct similar experiments where the 
negative control and culture medium are both serum-free, we favored maintaining a serum fraction in 
all cultures, as serum deprivation is known to dramatically influence cell behavior [27]. 
3. Results and Discussion 
3.1. Cell Migration Experiments 
Figure 3A,B show the migration of MCF-7 cells and MSC, respectively, through a microchannel 
and illustrate how migration distances were estimated. The migration behavior of the two cell types 
differed dramatically, with MCF-7 cells moving as a communal wave front, and MSC  
migrating independently. 
The migration of MCF-7 cells and MSC towards each other, towards equivalent control medium, 
and towards medium supplemented with 10% FBS was quantified (Figure 4A). Over the first 24 h, 
MCF-7 cell migration rates towards medium of higher serum content (10% FBS) were greater than 
towards MSC populations or towards control medium (5% FBS). However, at day 3 and day 5, 
migration rates towards MSC and higher serum content medium were similar, and with both rates 
statistically greater (p < 0.05) than towards control medium. Maximal MCF-7 wave front migration 
was observed between day 1 and day 3, and was estimated to be 137 ± 26 μm per day. The migration 
of MSC populations towards medium of higher serum content was significantly greater than towards 
either control medium or towards MCF-7 cell cultures (Figure 4B, p < 0.05 for day 1 and p < 10−7 for 
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days 3 and 5). The migration rate of MSC towards higher serum content medium was estimated to be 
210 ± 29 μm per day. In contrast, the migration rates of MSC towards MCF-7 populations and control 
medium were similar, but significantly slower than towards the serum-rich control medium (estimated 
to be 84 ± 14 and 83 ± 19 μm per day). Thus, MSC populations did not demonstrate preferential active 
migration towards MCF-7 cell cultures, unlike the MCF-7 populations, which did actively migrate 
towards MSC cultures. 
Figure 4. Quantification of MCF-7 and MSC migration. (A) At Day 1, MCF-7 migration 
towards higher serum content medium was greatest, whilst at Days 3 and 5, migration 
towards MSC and higher serum content medium was greater than towards control medium; 
(B) At all days, MSC migration towards higher serum content medium is greater than 
towards control medium or MCF-7 cultures (n = 14, error bars = one standard error of the 
mean, * indicates p < 0.05).  
 
Herein, we describe the fabrication and operation of a novel cell migration device, and use it to 
characterize MCF-7 breast cancer epithelial cells and bone marrow-derived MSC migration towards 
each other in interesting source-sink type assays. Various microchannel devices have been used in 
studies regarding the migration of cancer cells and other cell types [28,29], however the unique feature 
of the presented device is its array of 14 microchannels that connects source and sink culture 
reservoirs. During set-up, the entry of cells and/or culture medium into the microchannels was 
prevented by air bubbles (air-valves) that occupied each hydrophobic microchannel. Once monolayer 
cultures had been established in the isolated reservoirs, the air-valve bubbles were displaced, 
connecting the source and sink via the microchannel array. Various source-sink configurations were 
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used to determine if MCF-7 populations or MSC populations preferentially migrated towards each 
other relative to media having varying serum supplementation.  
Our results indicated that MCF-7 cells actively migrated both towards higher FBS concentrations 
and towards MSC populations (Figure 4A). This result is rational given the wealth of published data 
demonstrating that MSC populations secrete a number of chemokines including CXC ligand 12 
(CXCL12), CX3CL1, CXCL16, CC chemokine ligand 3 (CCL3), and CCL19 [30]. Among these 
CXCL12 plays a pivotal role in modulation of mobilization and homing of different cell types [31]. 
Breast cancer cells are known to respond to CXCL12 [32–35]. The MCF-7 cell response to MSC 
paracrine signals is also consistent with recent published data indicating that MSC secretions may play 
a key role in tumor development in vivo [21,36]. Contrary to the concept that MSC might be used to 
combat cancer, evidence suggests that MSC can support further tumor progression when infused into 
animal models by supporting the growth of cancer and possibly cancer stem cells [21]. The result may 
depend on the particular microenvironment in which the cells are found as well as on the chemokine 
pairing between different cell types within that environment. Cumulatively, these reports suggest that 
MCF-7 would respond to MSC paracrine signals. The migration device we describe here might be 
useful in characterizing cancer cell responses to the various panels of MSC secretions.  
MSC have been reported to migrate towards cancer lesions in vivo [14,18,37–40], and in vitro 
studies have shown that MSC actively migrate towards the MCF-7/Ras mutant cells [21]. Stem cells 
derived from adipose tissue also actively migrate towards breast cancer cells in vitro, likely as a 
response to tumor cell-derived platelet-derived growth factor BB (PDGF-BB) [41]. However, our 
results in Figure 4B indicate that bone marrow-derived MSC populations do not necessarily 
preferentially migrate towards MCF-7 cells in vitro. MSC migration within cancer lesions is believed 
to be largely in response to the localized inflammatory response [42], and in vitro cultures do not 
accurately mimic an inflammatory response. Therefore, it may not be logical to expect MSC to migrate 
towards MCF-7 cells in vitro. Nevertheless, the rationalization that MSC may migrate only in response 
to paracrine signals generated by immune cells prompts us to query if “death-signals” can be expected 
to reach their intended destination, or will they more likely be delivered to these by-stander immune 
cells? Additionally, will an alternative and perhaps unappreciated inflammatory response elsewhere in 
the body simply divert delivered MSC from their intended path? These are interesting questions that 
are beyond the scope of this paper, but we believe that improved migration assays like the one 
described here will facilitate characterization of cell migration behavior in response to  
chemotactic gradients. 
4. Conclusions 
In summary, we have outlined a novel microchannel cell migration device that enables 
quantification of cell population migration toward each other. Using this system we show that MCF-7 
cells actively migrate towards MSC populations, but that MSC do not actively migrate towards MCF-7 
populations in vitro.  
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